Pancreatic Islet-Like Cluster Differentiation With Gamma Secretase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pancreatic lineage cells, particularly islet-like clusters from pluripotent stem cells, suffer from inefficiencies in scalability, high reagent costs, and undesirably large proportions of unwanted cell types, while cryopreservation protocols face challenges in reproducibility and cell recovery, especially for human islet-like clusters.
Innovation Solution
A method involving the use of gamma secretase inhibitors and absence of thyroid hormone during differentiation stages, combined with a cryopreservation process using ethylene glycol and dimethylsulfoxide, to produce islet-like clusters with controlled ice formation, reducing unwanted cell types and enhancing recovery rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional differentiation protocols are used, then cell production can proceed, but undesirably large proportions of unwanted cell types are generated
Solution Approach 1:
The patent modifies chemical parameters in the differentiation medium, specifically using a gamma secretase inhibitor (GSI) at concentrations of 0.5-5 µM during stages ii and iii, and eliminating thyroid hormone (T3) from the protocol. These parameter changes redirect cell fate decisions to increase desired endocrine cell types while reducing unwanted cell populations, achieving both high purity and productivity
2Reliability
If manual nucleation induction is used in freezing protocols, then ice formation can be initiated, but reproducibility and scalability issues arise
Solution Approach 1:
The patent introduces an intermediary substance - a nucleating agent - that mediates ice crystal formation in a controlled manner. This agent enables reproducible and scalable freezing by providing a consistent mechanism for nucleation that does not depend on manual intervention, thereby improving both reliability and ease of manufacture
Solution Approach 2:
The patent replaces the mechanical/manual system of hand-based nucleation induction with a chemical/system-based approach using nucleating agents. This substitution eliminates variability associated with manual operations and enables automated, scalable freezing processes while maintaining controlled ice formation
3Manufacturing precision
If dissociation and re-association steps are included, then cell sorting is possible, but process control becomes difficult and scalability decreases
Solution Approach 1:
The patent extracts or removes the problematic dissociation and re-association steps from the differentiation protocol. By eliminating these steps entirely and maintaining cells in continuous suspension culture, the protocol achieves both precise control over cell population composition and full scalability, as the simplified process can be easily implemented in large-scale bioreactors
4Adaptability or versatility
If cryopreservation is not used, then on-demand production is possible, but manufacturing cannot be uncoupled from implantation
Solution Approach 1:
The patent applies cryopreservation as a preliminary action that allows complete manufacturing and quality control to be completed before patient-specific needs arise. By freezing differentiated cell clusters at the endocrine progenitor stage with high viability, the protocol enables advance production, comprehensive testing, and batch release, thereby uncoupling manufacturing from implantation while maintaining flexibility through controlled thawing and differentiation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a high enrichment of desired endocrine cells and reduces unwanted cell populations, with improved cell recovery and viability post-thaw, facilitating scalable and cost-effective production of islet-like clusters for therapeutic applications.
Implementation Method 1
Introducing controlled nucleation of ice formation in freezing protocols can overcome reproducibility and scalability issues associated with nucleation protocols based on induction by hand
Implementation Method 2
An efficient, GMP-compatible cryopreservation protocol is therefore a key element for cell therapy product development programs
Implementation Method 3
subsequently perform a directed differentiation of these clusters via a defined succession of intermediate stages using selected growth factors and small molecule compounds
Data Source
AI summary
The invention relates to the field of cell differentiation and cryopreservation, in particular of pancreatic lineage cells. It provides methods for differentiating cells of the pancreatic lineage, in particular to islet-like clusters. It further provides methods for freezing cells of the pancreatic lineage, in particular endocrine progenitor cells. It also provides new pancreatic lineage cell populations.